Recently, compromised DNA damage repair, including mutations in POLE exonuclease domain, mismatch repair pathways and HRR pathways, were found to be associated with higher tumor mutation burden (TMB), key clinicopathological features and patients’ prognosis, and could be used for further stratification in endometrial cancer (12, 20, 28–32). The gene discussed is POLE; the disease is endometrial cancer.